News
Get access to our breaking news, and company information
Press Releases
Beckman Coulter Life Sciences and Pillar Biosciences Sign Application Development Agreement for the Biomek NGeniuS System
INDIANAPOLIS – (October 31, 2022) – More companies around the world continue turning to Beckman Coulter Life Sciences, a global leader in laboratory automation and
Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference
NATICK, Mass. – August 31, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products
Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal™ Dx Colon Cancer Assay
– Highly-accurate, tissue-based, next-generation sequencing (NGS) test approved in China as a companion diagnostic for targeted colon cancer therapies NATICK, Mass. – August 22, 2022
Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit
NATICK, Mass. – August 5, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) products
Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx
– PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its
Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer
NATICK, Mass. – June 8, 2022 – (BUSINESS WIRE) – Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests